Sagimet Biosciences News and Activities
Presence
Sagimet Biosciences develops medicines for metabolic and liver diseases. Its main services are drug research and clinical development for healthcare providers, research partners, and patients with serious chronic conditions.
Sagimet Biosciences products and services overview:
- Drug discovery
- Clinical development
- Liver disease therapies
- Metabolic disease therapies
Revenue: ~$0 million
Employees: 80
Headquarters: San Mateo, United States (USA)
Sagimet Biosciences is one of the...
Sagimet Biosciences is a company listed under the stock ticker SGMT (US).
Executives
View the org chart displaying its 15 main executives
Most searched biographies at Sagimet Biosciences
- David Happel, Chief Executive Officer and Director
- George Kemble, Executive Chairman of the Board
- Paul Hoelscher, Director
Popular executive movements at Sagimet Biosciences
- Timothy Walbert, Director, has left the company (posted on June 15 2026).
- Andreas Grauer has joined the company as Chief Medical Officer (posted on April 21 2026).
- Eduardo Bruno Martins, Chief Medical Officer, is retiring (posted on April 21 2026).
Create your alert
to follow the executive moves at Sagimet Biosciences.
Biotechnology
Sagimet Biosciences has 2,431 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).
Popular M&A news in Biotechnology
- AdvanCell has just announced a $315 Million fundraising (posted on July 21 2026).
- Allotera Therapeutics has just announced a $35 Million fundraising (posted on July 21 2026).
- Draig Therapeutics has just announced a $65 Million fundraising (posted on July 21 2026).
Popular contacts in Biotechnology
News
Press releases by Sagimet Biosciences
- Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes | Sagimet Biosciences Inc.
- Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Sagimet Biosciences Inc.
- Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH | Sagimet Biosciences Inc.
- Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago | Sagimet Biosciences Inc.
- Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ | Sagimet Biosciences Inc.
- Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates | Sagimet Biosciences Inc.
- Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock | Sagimet Biosciences Inc.
- Sagimet Biosciences Provides Strategic and Corporate Updates | Sagimet Biosciences Inc.
- Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer | Sagimet Biosciences Inc
- Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Sagimet Biosciences Inc
- View more press releases Close
Social media about Sagimet Biosciences
- Sagimet Biosciences on Wikipedia, Google News & Yahoo Finance
- Sagimet Biosciences on LinkedIn, X (Twitter) & YouTube
